Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...
The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic methods for metabolic dysfunction–associated steatohepatitis (MASH).
Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...